GO:0042369 vitamin D catabolic process: Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042369 (vitamin D catabolic process) describes the biochemical breakdown of vitamin D compounds, including ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), into inactive or less active metabolites.
• The catabolic cascade is initiated by 25-hydroxylation in the liver and 1alpha-hydroxylation in the kidney, followed by 24-hydroxylation and side-chain oxidation that inactivate the hormone.
• Key enzymes include CYP2R1, CYP27B1, CYP24A1, and CYP3A4, which collectively determine vitamin D half-life and biological activity.
• Dysregulated vitamin D catabolism is linked to chronic kidney disease, hypercalcemia, and altered mineral homeostasis.
• Vitamin D bioavailability and catabolic rate vary between D2 and D3 forms, influencing clinical supplementation strategies.
• CRISPR-based knockout, knock-in, and overexpression models of catabolic enzymes enable precise dissection of vitamin D metabolism in vitro and in vivo.
Description
Vitamin D is a fat-soluble secosteroid that plays a central role in calcium and phosphate homeostasis, bone mineralization, and immune regulation. The term GO:0042369, vitamin D catabolic process, refers to the set of chemical reactions and pathways that result in the breakdown of vitamin D and its metabolites, including calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3). This catabolic process is essential for preventing vitamin D toxicity and for fine-tuning the availability of active hormone to target tissues. Understanding vitamin D catabolism is critical for researchers studying endocrine regulation, drug metabolism, and diseases such as chronic kidney disease and hypercalcemia. The catabolic machinery involves cytochrome P450 enzymes that sequentially oxidize the vitamin D backbone, ultimately producing water-soluble, excretable products. Because the same enzymes also participate in activation steps, the balance between activation and inactivation determines the net biological effect of vitamin D. This article integrates authoritative QuickGO annotation data with published literature to provide a research-grade overview of GO:0042369, covering its definition, molecular players, disease relevance, and experimental strategies for CRISPR-based interrogation.
vitamin D catabolic process At A Glance
| GO ID | GO:0042369 |
|---|---|
| GO term | vitamin D catabolic process |
| Ontology | biological_process |
| Synonym | calciferol catabolic process; calciferol catabolism; cholecalciferol biosynthesis; cholecalciferol biosynthetic process; ergocalciferol biosynthesis; ergocalciferol biosynthetic process; vitamin D breakdown; vitamin D catabolism; vitamin D degradation |
| Major function | Breakdown and inactivation of vitamin D compounds and their metabolites |
| Key enzymes | CYP24A1, CYP27B1, CYP2R1, CYP3A4 |
| Substrates | Ergocalciferol (vitamin D2), cholecalciferol (vitamin D3), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D |
| Cellular location | Mitochondria and endoplasmic reticulum of liver, kidney, and intestine |
| Related diseases | Chronic kidney disease, hypercalcemia, vitamin D toxicity |
What Is GO:0042369?
GO:0042369 (vitamin D catabolic process) is defined by QuickGO as the chemical reactions and pathways resulting in the breakdown of vitamin D, any of a group of related, fat-soluble compounds derived from delta-5,7 steroids that play a central role in calcium metabolism. Specific forms include calciferol (ergocalciferol; vitamin D2) and cholecalciferol (calciol; vitamin D3). In practice, this process encompasses the enzymatic oxidation, hydroxylation, and side-chain cleavage reactions that convert vitamin D and its active metabolites into inactive or excretable products, thereby terminating hormonal signaling.
Why Is vitamin D catabolic process Important in Cell Biology?
The vitamin D catabolic process is essential for maintaining vitamin D homeostasis and preventing toxicity from excessive intake or overproduction. It also modulates the availability of active hormone for calcium regulation, immune function, and cell differentiation. Dysregulation of catabolic enzymes such as CYP24A1 leads to hypercalcemia and renal complications, making this pathway a target for therapeutic and diagnostic research.
• Prevents vitamin D toxicity by degrading excess vitamin D and its active metabolites.
• Regulates the half-life and biological activity of 1,25-dihydroxyvitamin D.
• Influences calcium and phosphate homeostasis through controlled hormone inactivation.
• Implicated in chronic kidney disease progression and mineral bone disorders.
• Affects vitamin D bioavailability and dosing strategies for D2 versus D3 supplements.
• Provides targets for CRISPR knockout and knock-in studies of CYP24A1 and related genes.
• Links to drug metabolism pathways involving cytochrome P450 enzymes.
• Serves as a model for studying endocrine negative feedback regulation.
• Relevant to hypercalcemia of malignancy and granulomatous diseases.
• Enables research on vitamin D analogs with altered catabolic stability.
What Happens During vitamin D catabolic process?
Initial 25-Hydroxylation in the Liver
In simple terms: The first step in breaking down vitamin D happens in the liver, where an enzyme adds a hydroxyl group to the vitamin D molecule.
Vitamin D2 and D3 are transported to the liver bound to vitamin D-binding protein, where CYP2R1 and other cytochrome P450 enzymes catalyze 25-hydroxylation to form 25-hydroxyvitamin D. This metabolite is the major circulating form and serves as the substrate for subsequent activation or catabolic steps.
Activation to 1,25-Dihydroxyvitamin D
In simple terms: In the kidney, another enzyme adds a second hydroxyl group to make the active hormone.
CYP27B1 in the kidney converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, the biologically active form that regulates calcium and phosphate. This activation step is tightly regulated by parathyroid hormone, fibroblast growth factor 23, and vitamin D status.
24-Hydroxylation and Inactivation
In simple terms: A third enzyme adds a hydroxyl group that starts the process of shutting down the hormone.
CYP24A1 catalyzes 24-hydroxylation of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, initiating their catabolism. This enzyme is induced by 1,25-dihydroxyvitamin D itself, forming a negative feedback loop that prevents excessive hormone activity.
Side-Chain Oxidation and Excretion
In simple terms: Further oxidation breaks the molecule into smaller pieces that can be excreted.
Following 24-hydroxylation, further oxidation of the side chain by CYP24A1 and other enzymes produces calcitroic acid and other water-soluble metabolites that are excreted in bile and urine. This completes the catabolic process and terminates vitamin D signaling.
Alternative Catabolic Routes
In simple terms: Other enzymes can also break down vitamin D through different chemical steps.
CYP3A4 and other cytochrome P450 enzymes can catalyze alternative hydroxylation reactions on vitamin D metabolites, contributing to overall clearance. These pathways may become more prominent under certain physiological or pharmacological conditions.
Key Genes Involved in GO:0042369 vitamin D catabolic process
The following genes encode enzymes and proteins directly involved in the vitamin D catabolic process, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP24A1 | 24-hydroxylase initiating catabolism of 25(OH)D and 1,25(OH)2D | Target for knockout and inhibitor studies; linked to hypercalcemia |
| CYP27B1 | 1alpha-hydroxylase activating vitamin D; also can hydroxylate other positions | Knockout models reveal activation defects; relevant to CKD |
| CYP2R1 | 25-hydroxylase in liver, first step in metabolism | Polymorphisms affect vitamin D status; CRISPR models for hydroxylation |
| CYP3A4 | Alternative hydroxylation and catabolism of vitamin D metabolites | Drug interaction studies; overexpression models |
| VDR | Vitamin D receptor mediating feedback regulation of catabolic enzymes | Knockout models show altered CYP24A1 expression |
| DBP | Vitamin D-binding protein transporting vitamin D to liver and kidney | Knockout affects bioavailability and catabolism |
| LRP2 | Megalin receptor mediating renal uptake of DBP-vitamin D complexes | Knockout models show urinary loss of vitamin D metabolites |
| CYP27A1 | Alternative 25-hydroxylase with minor role in vitamin D metabolism | Double knockout with CYP2R1 reveals redundancy |
| FGF23 | Regulates phosphate and vitamin D metabolism, inhibits CYP27B1 | Knockout models show altered vitamin D catabolism |
| PTH | Parathyroid hormone stimulates CYP27B1 and regulates catabolism | In vivo models for endocrine regulation |
| CYP24A1 variants | Mutations causing impaired catabolism and hypercalcemia | Knock-in models for idiopathic infantile hypercalcemia |
| SLC34A1 | Phosphate transporter affecting vitamin D metabolism indirectly | Knockout models for mineral disorders |
| Klotho | Co-receptor for FGF23, modulates vitamin D catabolism | Knockout models show premature aging and hypervitaminosis D |
| CYP2J2 | Epoxygenase with potential vitamin D hydroxylation activity | Overexpression studies for alternative pathways |
| CYP4F2 | Omega-hydroxylase of vitamin D metabolites | Knockout models for catabolic redundancy |
| ABCB1 | Efflux transporter affecting vitamin D metabolite distribution | Knockout models for pharmacokinetics |
| GC | Group-specific component (vitamin D-binding protein) gene | Knockout affects vitamin D transport and catabolism |
| CYP24A1 promoter | Regulatory region for feedback induction by 1,25(OH)2D | CRISPR knock-in reporters for transcriptional studies |
How Is vitamin D catabolic process Regulated?
The vitamin D catabolic process is tightly regulated by negative feedback: 1,25-dihydroxyvitamin D induces CYP24A1 expression through the vitamin D receptor (VDR), accelerating its own inactivation. Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) reciprocally regulate CYP27B1 and CYP24A1 to maintain calcium and phosphate homeostasis. Additionally, vitamin D-binding protein (DBP) and megalin (LRP2) influence the delivery of vitamin D metabolites to catabolic tissues, thereby modulating the rate of degradation.
vitamin D catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP24A1 | Idiopathic infantile hypercalcemia | Knockout or knock-in point mutation in cell lines and mice |
| CYP27B1 | Chronic kidney disease, vitamin D-dependent rickets | Kidney-specific knockout models |
| VDR | Hereditary vitamin D-resistant rickets | Knockout and overexpression in osteoblast-like cells |
| FGF23 | Hypophosphatemic rickets, CKD | Transgenic overexpression and knockout mice |
| DBP | Vitamin D deficiency and bioavailability | Knockout models for transport studies |
Chronic Kidney Disease and Mineral Bone Disorder
In chronic kidney disease, reduced renal mass leads to decreased CYP27B1 activity and impaired vitamin D activation, while CYP24A1-mediated catabolism may be altered, contributing to hypocalcemia and secondary hyperparathyroidism. These changes are central to renal osteodystrophy and vascular calcification.
Hypercalcemia and Vitamin D Toxicity
Loss-of-function mutations in CYP24A1 cause idiopathic infantile hypercalcemia due to impaired catabolism of active vitamin D. Similarly, excessive vitamin D intake can overwhelm the catabolic capacity, leading to hypercalcemia and nephrocalcinosis.
Granulomatous Diseases and Lymphoma
In granulomatous diseases such as sarcoidosis and some lymphomas, extrarenal CYP27B1 activity produces excess 1,25-dihydroxyvitamin D, while catabolic clearance may be insufficient, resulting in hypercalcemia.
From vitamin D catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CYP24A1 loss alter vitamin D metabolite levels? | CYP24A1 knockout cell line (e.g., HEK293 or HepG2) |
| How do point mutations in CYP24A1 affect enzyme activity? | CRISPR point mutation knock-in in cell lines |
| Can we track CYP24A1 expression in real time? | Tagged knock-in with fluorescent reporter |
| Does overexpression of CYP3A4 enhance vitamin D clearance? | CYP3A4 overexpression stable cell line |
| What is the role of VDR in feedback regulation? | VDR knockout and rescue models |
| How does DBP affect vitamin D catabolism? | DBP knockout mouse or cell model |
How to Study the vitamin D catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Vitamin D metabolite concentrations | Quantifying catabolic products in serum or cells |
| CRISPR knockout screen | Genes affecting vitamin D catabolism | Identifying novel regulators |
| RNA-seq | Transcriptional changes in catabolic enzymes | Studying feedback regulation |
| Enzyme activity assay | Catalytic rate of CYP24A1 or other enzymes | Kinetic characterization of mutants |
| Western blot | Protein expression of catabolic enzymes | Validating knockout or overexpression |
| Immunohistochemistry | Tissue localization of enzymes | Assessing kidney or liver expression |
| Reporter gene assay | CYP24A1 promoter activity | Screening for regulators of catabolism |
| CRISPR knock-in | Tagged enzyme for live-cell imaging | Tracking catabolic enzyme dynamics |
LC-MS/MS for Vitamin D Metabolites
Liquid chromatography-tandem mass spectrometry is the gold standard for quantifying vitamin D metabolites, including 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and catabolic products such as calcitroic acid, allowing direct assessment of catabolic flux.
CRISPR Screens for Catabolic Regulators
Genome-wide CRISPR knockout or activation screens can identify genes that modulate vitamin D catabolism, using metabolite readouts or reporter assays for CYP24A1 expression.
Transcriptomics and RNA-seq
RNA sequencing of cells treated with vitamin D or its analogs reveals changes in expression of catabolic enzymes and regulatory factors, providing insights into feedback mechanisms.
Enzyme Activity Assays
In vitro assays using recombinant CYP24A1 or cell lysates measure the conversion of radiolabeled or fluorescent substrates to hydroxylated products, enabling kinetic analysis of catabolic enzymes.
How CRISPR Can Be Used to Study GO:0042369 vitamin D catabolic process
Knockout
CRISPR knockout of CYP24A1 or CYP27B1 in cell lines such as HEK293 or HepG2 abolishes specific catabolic steps, leading to accumulation of upstream metabolites and providing a clean model to study enzyme function and feedback.
Point Mutation
Introducing disease-associated point mutations (e.g., in CYP24A1) via CRISPR base editing or homology-directed repair allows researchers to dissect the impact of specific amino acid changes on catalytic activity and substrate specificity.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous catabolic enzyme loci enables real-time tracking of expression, localization, and interaction dynamics under physiological conditions.
Overexpression
CRISPR activation or lentiviral overexpression of catabolic enzymes such as CYP3A4 or CYP24A1 can enhance vitamin D clearance, useful for studying toxicity thresholds and drug interactions.
How EDITGENE Supports vitamin D catabolic process Research
Researchers studying vitamin D catabolic process-related genes often need to determine whether a candidate gene is causally involved in metabolite clearance, feedback regulation, or disease progression. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for vitamin D catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| FGF23 Knockout HEK293 Cell Line | EDJ-KQ662 | Human | 8074 | Details Get a Quote |
| CYP3A4 Knockout HEK293 Cell Line | EDJ-KQ1389 | Human | 1576 | Details Get a Quote |
| CYP24A1 Knockout HEK293 Cell Line | EDJ-KQ3491 | Human | 1591 | Details Get a Quote |
| CYP27B1 Knockout HEK293 Cell Line | EDJ-KQ3766 | Human | 1594 | Details Get a Quote |
| FGF23 Knockout HeLa Cell Line | EDJ-KQ18297 | Human | 8074 | Details Get a Quote |
| CYP27B1 Knockout A-549 Cell Line | EDJ-KQ24488 | Human | 1594 | Details Get a Quote |
| CYP24A1 Knockout A-549 Cell Line | EDJ-KQ25281 | Human | 1591 | Details Get a Quote |
| CYP24A1 Knockout HCT 116 Cell Line | EDJ-KQ25282 | Human | 1591 | Details Get a Quote |
| CYP24A1 Knockout HeLa Cell Line | EDJ-KQ25283 | Human | 1591 | Details Get a Quote |
| CYP27B1 Knockout HCT 116 Cell Line | EDJ-KQ25851 | Human | 1594 | Details Get a Quote |
| CYP27B1 Knockout HeLa Cell Line | EDJ-KQ25852 | Human | 1594 | Details Get a Quote |
| CYP3A4 Knockout HeLa Cell Line | EDJ-KQ53053 | Human | 1576 | Details Get a Quote |
| CYP3A4 Knockout A-549 Cell Line | EDJ-KQ61518 | Human | 1576 | Details Get a Quote |
| FGF23 Knockout A-549 Cell Line | EDJ-KQ63309 | Human | 8074 | Details Get a Quote |
| CYP3A4 Knockout HCT 116 Cell Line | EDJ-KQ70010 | Human | 1576 | Details Get a Quote |
Displaying Records 1 To 15 Of 16 Records
Frequently Asked Questions About vitamin D catabolic process
What is GO:0042369?
GO:0042369 is the Gene Ontology term for vitamin D catabolic process, describing the biochemical breakdown of vitamin D compounds such as ergocalciferol and cholecalciferol.
What genes are involved in vitamin D catabolic process?
Key genes include CYP24A1, CYP27B1, CYP2R1, CYP3A4, VDR, and DBP, which encode enzymes and regulatory proteins in the pathway.
Where does vitamin D catabolism occur?
It occurs primarily in the liver, kidney, and intestine, involving mitochondrial and microsomal cytochrome P450 enzymes.
What is the main enzyme for vitamin D catabolism?
CYP24A1 is the principal enzyme that initiates catabolism of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D.
How is vitamin D catabolism regulated?
It is regulated by negative feedback via 1,25-dihydroxyvitamin D inducing CYP24A1, and by PTH and FGF23 signaling.
What diseases are linked to defective vitamin D catabolism?
Idiopathic infantile hypercalcemia, chronic kidney disease, and granulomatous diseases with hypercalcemia are linked to impaired catabolism.
How can CRISPR be used to study vitamin D catabolism?
CRISPR knockout, knock-in, and overexpression models allow precise manipulation of catabolic genes to study their function and regulation.
What methods measure vitamin D catabolic activity?
LC-MS/MS, enzyme activity assays, RNA-seq, and reporter assays are commonly used to quantify catabolic flux and enzyme expression.
What is the difference between vitamin D2 and D3 catabolism?
Both forms undergo similar catabolic steps, but differences in bioavailability and enzyme affinity can affect clearance rates.
Why is vitamin D catabolism important for health?
It prevents vitamin D toxicity, maintains calcium homeostasis, and modulates immune and cellular functions.
Conclusion
GO:0042369 (vitamin D catabolic process) is a critical biological pathway that controls the lifespan and activity of vitamin D hormones. Its dysregulation contributes to hypercalcemia, chronic kidney disease, and other disorders, making it a rich area for CRISPR-based research. By leveraging knockout, knock-in, and overexpression models, researchers can dissect the molecular players and regulatory networks of vitamin D catabolism, ultimately informing therapeutic strategies.
References
- 1. Delrue C et al.. 2023. Vitamin D and Vitamin D-Binding Protein in Health and Disease.. Int J Mol Sci 24(5) PMID: 36902073
- 2. Borel P et al.. 2015. Vitamin D bioavailability: state of the art.. Crit Rev Food Sci Nutr 55(9):1193-205 PMID: 24915331
- 3. Chau YY et al.. 2012. Vitamin D in chronic kidney disease.. Indian J Pediatr 79(8):1062-8 PMID: 22544696
- 4. Jones G. 2008. Pharmacokinetics of vitamin D toxicity.. Am J Clin Nutr 88(2):582S-586S PMID: 18689406
- 5. Fleet JC. 2025. Differences in the absorption and metabolism of vitamin D(2), vitamin D(3), and 25 hydroxyvitamin D.. J Steroid Biochem Mol Biol 249:106718 PMID: 40043817
- 6. Harrison HE. 1981. Vitamin D.. Prog Clin Biol Res 61:95-108 PMID: 7033977
- 7. DeLuca HF. 1976. Vitamin D endocrinology.. Ann Intern Med 85(3):367-77 PMID: 183579
